Ben Auspitz, F-Prime
From $30M launch round to $400M buyout deal — with $250M upfront — in 10 short months
F-Prime’s Ben Auspitz has turned a modest investment in his newly launched biotech Modis Therapeutics into a quick score on the M&A side. And the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
